Schaffhausen, Switzerland -Occlutech, a leading innovator of implants to treat structural heart disease,today announced that it has obtained European CE Mark approval for its Left Atrial Appendix, (LAA), occluder. The device is a specifically designed implant for theminimally invasive closure of the LAA, a procedure that minimizes the risk of strokes in patients suffering from atrial fibrillation…
